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The early stages of drug discovery rely on hit-to-lead programs, where initial hits undergo partial
optimization to improve binding affinities for their biological target. This is an expensive and
time-consuming process, requiring multiple iterations of trial and error designs, an ideal scenario
for applying computer simulation.  However, most state-of-the-art modeling techniques fail  to
provide a fast and reliable answer to the induced-fit protein-ligand problem. To aid in this matter,
we present FragPELE, a new tool for  in silico hit-to-lead drug design, capable of growing a
fragment from a bound core while exploring the protein-ligand conformational space. We tested
the ability of FragPELE to predict crystallographic data, even in cases where cryptic sub-pockets
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open due to the presence of particular R-groups. Additionally, we evaluated the potential of the
software on growing and scoring five congeneric series from the 2015 FEP+ dataset, comparing
them  to  FEP+,  SP  and  Induced-Fit Glide, and  MMGBSA  simulations.  Results  show  that
FragPELE could not only be useful for finding new cavities and novel binding modes in cases
where standard docking tools can not, but also to rank ligand activities in a reasonable amount of
time and with acceptable precision.
INTRODUCTION
Hit to lead (H2L) efforts in early drug discovery pursue the optimization of potency as well as
other properties such as solubility, absorption, chemical stability, and toxicity, to name a few.1
Regarding potency, the most natural way for medicinal chemists to optimize a new chemical
entity  is  to  gain  further  interactions  with  the  targeted  receptor  by  growing  the  initial  seed
compound.  Generally,  hits  are  grown  into  leads  by  gaining  electrostatic  and  hydrophobic
interactions with their receptors. It has been described that the evolution of a hit to a clinical
candidate yields, on average, gains of molecular weight (MW) ca. 85Da and increasing structural
complexity.2
The “growing” strategy is especially relevant within the fragment-based drug design (FBDD)
paradigm, where the starting points are typically low MW compounds with marginal potency on
the receptor (typically double-digit μM). Fragments can either be linked or grown so that their
potencies can be brought down to the nM level. However, drug-hunting teams applying FBDD
primarily  resort  to  fragment  growing with  the  help  of  a  series  of  detailed  experimental  3D
information, above all X-ray.3,4
Decorating a known chemical core on one or more points (R-groups) is not an obvious task,
even when access to rich structural 3D information is available. Receptor motion both at the
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side-chain  and  backbone  level  and  the  role  of  solvent  are  the  main  factors  hampering  a
straightforward estimation on what type of chemical  groups should be added to an R-group.
Moreover, binding sites might undergo larger rearrangements as a response to ligand probing and
open up cryptic  sub-pockets.  A prototypical  example  of  the  latter  behavior  can  be  seen  by
comparing the structure of epidermal growth factor receptor (EGFR) when bound to the first-
generation inhibitor Gefitinib5 vs. second-generation inhibitor Lapatinib.6 The structure of the
latter would have never been guessed by inspecting the X-ray of the EGFR-Gefitinib complex as
significant  rearrangements  are  needed  to  accommodate  a  much  bulkier  R-group beyond  the
gatekeeper residue.
Computational  modeling  is  now  a  mainstream  technology  with  applications  in  all  early
discovery tasks, from receptor prioritization, binding site detection and druggability analysis, to
virtual screening and lead optimization. Structure-based in silico R-group exploration is not an
exception, which can be handled by a variety of techniques. A quick and useful approach is to
build a focused combinatorial library around the known core whose X-ray crystal structure is
available and dock the whole series on the latter.7 This can be done in an unguided fashion or
directed by pharmacophoric or positional restraints to keep the core at the known position. A
similar  approach  is  to  use  generative  models  such  as  recurrent  neural  networks  (RNN)  or
variational autoencoders (VAE)8 to grow drug-like fragments onto an initial compound to dock
them subsequently.  An additional  approach is  to  use de novo algorithms with the seed core
placed at  the  binding site.  Plenty of programs and modeling  platforms offer such strategies.
Among  the  most  thoroughly  tested  de  novo  algorithms  we  find  LigBuilder2.09 and
Autogrow3.0.10 Some of  them are  clever  enough to  incorporate  synthetic  feasibility  such as
SYNOPSIS11 and NAOMINext.12 However, most of them are based on a rigid representation of
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the binding site,13 which severely limits the generation of high-quality geometries and binding
energies  for  the grown derivatives.  Some attempts  at  incorporating  receptor  flexibility  when
expanding R-groups have been developed. For instance, induced-fit Glide, LEA3D,14 SkelGen,15
and OpenGrowth,16 where ligand and local  side chains are sampled to take into account  the
dynamics of the binding site.
R-group exploration can be also carried out with a variety of molecular dynamics (MD) based
techniques  that  are  generically  used  for  studying  a  series  of  compounds  against  the  same
receptor. These approaches, although computationally more expensive, allow to partially capture
binding  site  flexibility.  Some  approaches  worth  mentioning  are  Linear  interaction
approximation,17 MMPB(SA) and MMGB(SA).8 However, they are not specifically designed for
R-group  growth  of  a  seed  molecule  placed  at  a  binding  site.  The  most  rigorous  but
computationally  expensive  MD-based  techniques  with  R-group  applicability  are  based  on
alchemical free energy methods.19,20 By way of thermodynamic cycles, they mutate a starting
structure to  a  final  structure providing a rigorous relative  change in  binding free energy.19,21
While this technology is clearly among the most reliable for estimating binding free energies, it
comes, however, with a considerable computational cost.
A dynamic exploration of a growing molecule in a binding site can also be explored with
Monte Carlo (MC) algorithms, in fact, the program BOMB has been successfully applied to a
variety  of  pharmaceutically  relevant  targets.  This  technique  grows  several  fragments  by
replacing substituents of ligands that can be previously placed in the binding site or isolated.
Conformational  searches  are  performed  for  each  molecule  and  conformers  are  optimized,
evaluating then the lowest-energy conformers with quick scoring functions.22
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MC  codes  have  been  widely  used  to  achieve  faster  explorations  of  the  protein-ligand
conformational  space.  For  instance,  BLUES apply  a  nonequilibrium candidate  Monte  Carlo
(NCMC)  method  to  improve  sampling  of  ligand  binding  modes.23 A  similar  approach  is
represented by our platform PELE (Protein Energy Landscape Exploration).  It  implements  a
heuristic MC procedure including complex protein structure prediction techniques in each MC
move.24 Successful  applications  in  drug  design  include  poses  prediction,25 binding  path
sampling26,27 and binding free energy prediction  when coupled to MSM28,29.  Furthermore,  we
recently introduced an adaptive  sampling procedure,  AdaptivePELE, improving the sampling
performance  (speed)  by  an  order  of  magnitude.30 Overall,  the  platform  is  very  efficient  at
sampling  rugged  potential  energy  surfaces  and  avoiding  entrapment  in  local  minima  when
reproducing, for instance, ligand-receptor induced-fit complex formation.
Given its sampling efficiency, it was decided to test whether PELE could be adapted to R-
group growth in the context of H2L. Herein, we describe a new protocol called FragPELE, based
on gradually growing an R-group for a bound ligand in a series of steps. It has been devised to
fall  midway  between  the  expensive  alchemical  free  energy methods  and the  quick  standard
docking-based techniques. We report a first benchmark where we reveal that FragPELE is not
only able to generate good geometries even for complex cases involving significant induced-fit
effects, but can also yield binding energy estimates that are not far off from those obtained by the
more  expensive  alchemical  free  energy  methods.  Interestingly,  FragPELE  shows  good
performance at locating cryptic sub-pockets in a known binding site. Overall, the methodology
seems to be a promising strategy to explore R-group growth while capturing induced fit effects
and represents a further addition to in silico H2L techniques.
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METHODS
Computational method. FragPELE is based on the PELE software, which combines an MC
stochastic approach with protein structure prediction techniques. Briefly, in PELE each MC step
is composed by three processes: 1) initial perturbation, where the ligand is randomly rotated and
translated and the atoms of the backbone of the protein are displaced through the use of normal
modes; 2) side-chain sampling, where an experimental rotamer library is used to reposition side
chains  in  response  to  the  initial  perturbation  and;  3)  final  minimization,  where  the  overall
structure is relaxed. More details on the PELE method can be found on our recent book chapter.31
In addition, FragPELE also uses BioPython32 and ProDy33 external libraries. 
The  software  is  intended  to  automatically  grow  one  or  more  fragments  onto  different
hydrogens of the same scaffold employing consecutive steps (epochs), following the technology
recently introduced in AdaptivePELE.30 To efficiently sample re-arrangement of the system as
the fragment  is grown, several independent  PELE simulations  are run at  each epoch, adding
extensive side-chain sampling, normal modes backbone sampling and minimization procedures.
The overall method, shown in Figure 1, involves: preparation (1), fragment linkage (2), fragment
reduction (3), fragment growing (4) and sampling/scoring (5).
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Figure 1.  Schematic overview of the procedure to run Frag-PELE. In yellow we underline the
heavy atoms that will be connected in the fragment linkage. 
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1 - Preparation. FragPELE is intended to automatically grow one or more fragments onto the
same scaffold. For this, a previously prepared protein-ligand complex must be provided in PDB
format (the complex can be an X-ray co-crystal structure, a docked pose for a chemical core
generated by docking, etc.).  Protonation and structural issues such as missing loops, missing
atoms, and multiple occupancies must be solved previously. Metal ions, cofactors, and structural
waters can be included as part of the receptor. All systems were prepared with Schrödinger’s
Protein  Preparation  Wizard34 including  H-bond optimization  using  PROPKA35 at  pH 7.  The
fragments  to be grown must  be provided in  separate  PDB files  with the correct  protonation
states, together with a tabular input file where the user must specify the path to the fragment files
and the atoms to be linked. 
2 - Fragment linkage.  The purpose of this  stage is to link a given fragment to the docked
chemical core at a specified position; the atoms provided in the previous step will be involved in
the creation of a new single covalent bond. To achieve this, the coordinates of the hydrogens
associated  with  these  heavy atoms  will  be  aligned,  and the  hydrogens  will  be  subsequently
deleted to produce the new bond (Figure 2A-2B). If any of the chosen heavy atoms have more
than one hydrogen, the user can specify which one to use, controlling the resulting stereocenter,
otherwise,  the  algorithm automatically  selects  the  one  that  produces  fewer  clashes  with  the
protein.  Terminal  heavy  atoms  other  than  hydrogen  atoms  are  automatically  replaced  for  a
hydrogen.
In some cases, the addition of the fragment would lead to intramolecular clashes with the core
of the molecule. In this scenario, rotations of 10 degrees along the axis of the new bond are
successively performed until a more favorable position is located. If no position is found, the
resolution of the rotamer is increased to 1 degree; the program stops if no position is found at this
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resolution. At the end of this stage, the terminal atom of the initial core is replaced with the
fragment to grow, obtaining the complete ligand. Additionally, the force field parameters (2005
OPLSAA)36 of the ligands (initial and grown) are generated.
3 - Fragment Reduction. This stage reduces the parameters of the atoms in the fragment to be
later grown dynamically within the binding site. The specific non-bonding terms being reduced
are the next:  σ Lennard-Jones potential (Van Der Waals radii),  q (charge) of the electrostatic
potential, and the  r (equilibrium distance) of the bonding parameters. The reduction is applied
differently for each parameter. The initial σo and qo are computed following equation 1 and 2,
respectively where σ is the Van Der Waals radii of the grown ligand, qH are the charges of the
hydrogen that has been replaced from the protein-ligand complex, N is the number of atoms of




                                                      qo = 
qH
( L+1 ) × N
                     (2)
The computation of the initial bond distances (ro) follows equation 3, where r is the grown
ligand equilibrium distance, except for the initial distance involving the linking atoms, that is
calculated with the equation 4, being rH the equilibrium distance of the bond between the atoms
of the core and the hydrogen atom that has been replaced. The distance between the fragment and
the core  is  increased  in  comparison with the  bonds of  the fragment  to  avoid intramolecular
clashes  at  the  beginning  of  the  simulation.  At  the  same  time,  the  (resulting)  charge  of  the
hydrogen atom is spread and reduced proportionally to the number of GS into the different atoms
of the fragment to simulate the electrostatics of the initial hydrogen. Notice that this charge is
initially reduced by GS since larger charge values introduced artifacts in the initial sampling.
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Angles  and  dihedrals  are  initially  kept  the  same. A  default  value  of  10  for  GS is  chosen,
providing a good balance between a smooth and fast growing, and avoiding large artifacts in the
H-like volume of the fragment produced by too low or too high L. 
 ro = 
r
L+1            (3)
                                                    rlink = rH +
r − rH
L+1                            (4)
Figure 2. Growing of a methyl onto a benzene core. Carbon and hydrogen atoms are depicted in
green  and  gray,  respectively.  Initially,  (A)  the  fragment  and  the  core  are  separated  as  two
different entities; (B) the fragment is correctly placed by aligning and deleting the hydrogens that
will  be  involved  in  the  creation  of  the  new  covalent  bond.  Finally,  (C)  the  fragment  is
miniaturized and ready to be grown along the simulation in 10 growing steps.
4  -  Fragment  growing.  Starting  from the  concept  introduced  by  AdaptivePELE,  the  new
fragment is grown in a series of epochs, called growing steps (GS). At each GS, parallel MC
simulations  (47  simulations  of  6  MC steps  by  default)  are  run  after  linearly  increasing  the
parameters of the fragment following equation 5 (where X is σ, q and r, and S is the current GS).
To increase the sampling, after each epoch all resulting structures are  clustered using protein-
ligand contact maps and the k-means algorithm. For each cluster,  the structure with the best
interaction energy is used as input for the next growing step. The interaction energy is computed
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subtracting the energy of the protein and the ligand (both isolated) to the total energy of the
system [E(AB) -E(A) -E(B)]. The energy is  calculated with equation 6,  having into account
bonding, non-bonding and solvation energy terms.  Thus, the fragment growing is an iterative
process where the output structures of the current GS are the input for the next iteration. Figure 3
illustrates the process for growing a chlorophenyl fragment onto amino-indazole.
                     Xstep = λX ; λ = 
1
L− S+1         (5)
E=Ebond +Eangle+E torsion+E improper torsion+ Evdw+Eele+ ΔG solv , pol+Gsolv ,npol+Econstraints                         (6)
5 - Sampling simulation and analysis. Once the ligand is completely grown, a longer PELE
simulation is performed to score the grown molecule, by default involving 20 MC steps. In this,
side-chain sampling is emphasized to thoroughly map the protein-ligand conformational space,
to obtain all possible rearrangements of the complex. The score is computed as the mean of the
25 percent  lowest  values  of  interaction  energies  along with  the  simulation,  to  minimize  the
effects of outliers and false positives.
As a summary, the standard protocol to grow one fragment into a core with FragPELE consists
of 10 GS, containing 47 independent MC simulations of 6 PELE steps each, and a final sampling
simulation  of  20 PELE steps.  Every GS results  on 5 different  clusters  to  initialize  the  next
iteration. Moreover, to restrict the core’s perturbation, all simulations are configured with low
translations,  0.05-0.10  Å,  and  rotations,  0.02-0.05  radians,  and  allowing  only  displacements
within  a  box  of  4  Å  radius.  In  terms  of  computation  time,  growing  one  fragment  takes
approximately 1 hour on two Intel Xeon Platinum 8160 processors (2x24 processor units).
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Figure 3. Example of a FragPELE simulation where a chlorophenyl fragment is grown onto an
amino-indazole in 10 growing steps. Carbon and nitrogen atoms of the core are represented in
gray and blue, respectively. Carbon and chlorine atoms of the fragment are represented in orange
and green, respectively. For each panel, the structure and the values of the force field parameters
are shown in the inset.
Benchmark preparation.  Two main different tests have been carried out. First, a structural
validation of the capacity of reproducing X-ray crystal structure poses was performed. Second,
we  evaluated  the  ability  of  FragPELE  at  successively  growing  fragments  and  scoring  their
affinity. 
Structural benchmark.  This benchmark aims to evaluate whether FragPELE can reproduce
native poses of an X-ray crystal structure when growing in different scenarios. A total  of 13
systems were analyzed, where four of them were focused on cryptic sub-pocket identification.
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The first validation consisted of growing part of the ligand that has been previously removed
from the original  X-ray crystal  structure.  We have called this  concept  “self-growing”.  Thus,
simulations will start from the crystal with the remaining scaffold already placed in the binding
site and the part of the ligand that has been previously removed will be grown to try to reproduce
the native pose. For this, three different systems with available crystallographic data were chosen
from the  FEP+ Benchmark,37 as  all  ligands  were  obtained  from FBDD efforts.  The  chosen
systems were:
1. Major Urinary Protein (MUP-I) in complex with sec-butyl-thiazoline (PDB code: 1I06).38
2. p38α kinase  or  mitogen-activated  protein  kinase  14 (MAPK14)  co-crystallized  with  3-
(benzyloxy)pyridin-2-amine (PDB code: 1W7H).39 
3. Bacterial DNA ligase in complex with an azaindazol (PDB code: 4CC6).40 
All fragments were first manually removed from their respective X-rays by replacing them by
a hydrogen atom (Table S1). Then, these fragments were grown again and the quality of the
results was assessed by computing the heavy atom root mean square deviation (RMSD) of the
core, fragment and the entire ligand against the initial crystal structure. p38 and DNA ligase were
tested with and without structural water molecules; no structural water molecules were found in
MUP-I due to the high hydrophobicity of the binding site. 
The second structural test consisted of growing one or more fragments onto an X-ray scaffold
to reproduce the interactions found in a second X-ray structure containing the entire ligand. We
refer to this concept as “cross-growing”. 
For this, four different systems were used, from which we had at least two crystal structures,
one co-crystallized with a core ligand and a second one co-crystallized with a larger ligand,
which could be generated by growing a fragment onto the core ligand. The heavy atom RMSD of
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the  core,  fragment  and fully  grown ligand  against  the  second  X-ray  structure  were  used  to
evaluate the quality of the results. Key ligand-protein interactions of the native structure were
compared with the ones found in the structures retrieved by FragPELE, to evaluate the ability of
the software at reproducing native interactions while growing.
The four systems used are, T4 Lysozyme, p38α kinase, the tyrosine-protein kinase JAK2, and
beta-secretase 1 (BACE). Scaffold and fragments for all systems are shown in Table S2. Water
molecules were deleted from all systems, except for the growing of BACE (4DJU to 4DJW), in
which the waters were kept to reproduce an interaction between the fragment and the water
molecules.
Finally, we tested the ability of FragPELE in sub-pocket identification. Cryptic sub-pockets are
hidden cavities  within a  well-known binding site,  which only open up when induced by the
presence of particular R-groups. This benchmark evaluated whether FragPELE could reproduce
the cryptic  sub-pocket  opened when growing the  second-generation  inhibitor  lapatinib  (PDB
code: 1XKK)41 from the first-generation inhibitor gefitinib (PDB code: 4WKQ) on the epidermal
growth factor receptor (EGFR). As gefitinib had too many rotatable bonds to sample all possible
ligand conformations in an acceptable amount of time, we decided to delete its solvent-exposed
R-group, generally used to modify the ADME properties of the drug (Table S3), as this part is
irrelevant for the present study. To evaluate results, we focused the analysis on two side chains
lining the sub-pocket, M766 and F856. As it is seen in the crystal structure, the former must
move aside to generate enough space to place the bulky fragment, and the latter is engaging the
drug in a crucial pi interaction with the fluoro-phenyl ring. 
In  addition,  we tested  the  reliability  when growing  a  fragment  that  decreases  the  binding
affinity of its precursor. Thus, FragPELE was tested at growing a small series of MAPK p38
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inhibitors, starting from the inhibitor found in crystal structure 1A9U.42 IC50s are available for
all analogs (Table S4) but not their binding modes. The series was obtained from CHEMBL43
(CHEMBL71403,44 CHEMBL69929),45 where we made sure the members have a wide range of
experimental values. The system deals with a prototypical ATP-competitive kinase inhibitor that
anchors a  heterocycle to the central  hinge residue (in this  case M109) via  an H-bond.40 We
hypothesize that the less potent ligands within the series have too bulky R-groups which cannot
be  accommodated.  To  verify  this,  structures  retrieved  from  FragPELE  simulations  were
compared to the initial pose of the only analog whose X-ray structure is available.
Growing and scoring benchmark. We evaluated  FragPELE’s performance at  growing and
scoring fragments in 5 systems on the FEP+ benchmark of Steinbrecher et al.:37 T4 Lysozyme,
DNA ligase, MUP-I, JAK-II, and p38. These systems were carefully chosen in order to have
variability on the fragment size, binding site characteristics, and MW correlation.  We removed
those cases where the molecule was not amenable to R-group growing methodologies, such as
molecules  formed by single rings  or  alchemical  transformations  of  heavy atoms of  the  core
(Table S5 to S9). Standard Induced-Fit Glide calculations (with OPLS3 force field46) were run
and our results were compared to FEP+, Glide SP docking and MM-GBSA, as provided in the
benchmark paper.37
Set up. Structures with missing atoms in side-chains were corrected using the 3D builder of
Maestro,47 followed by energy minimization of these residues with the OPLS-2005 force field36
and  the  implicit SGB  solvent.48 The  same  force  field  and  solvent  was  used  in  FragPELE
simulations. As  stated,  all  systems  were  prepared  with  Schrödinger’s Protein  Preparation
Wizard34 including H-bond optimization using PROPKA35 at pH 7.
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RESULTS AND DISCUSSION
The  method  was  validated  in  terms  of  generating  good  binding  geometries  (structural
validation) and scoring congeneric series of ligands.
Structural Validation. RMSD of the self-growing test are shown in Table 1 (upper panel). All
systems show a heavy atom RMSD values under 2 Å, retrieving native-like conformations for
fragment and core. However, close attention must be paid to water molecules in hydrated sites,
as the RMSD slightly increase when removing them. A clear example is shown in Figure S1,
where the core and fragment RMSDs increase when water molecules are not present; the main
reason being that the ligand tends to occupy the steric space left by the removed waters despite
no further interactions are gained. Finally, results from the DNA ligase (4CC6) system, shown in
Figure 4, illustrate that FragPELE is prone to recover native interactions of the complex, as the
trifluoride of the fragment is found to rapidly interact with the surrounding hydrophobic residues,
stabilizing this conformation along the simulation.
Cross-growing results are seen in Table 1 (bottom panel). All RMSD values excepting the p38
system fall below 2 Å. A closer inspection at the best structures for p38 (Figure 5) revealed that
the naphthyl had been rotated almost 180 degrees, increasing the RMSD of the fragment. As
depicted in Figure 5, the addition of the fragment causes a displacement of K53 towards a crucial
pi-cation  interaction  with the ligand,  and yields  a  native-like  pose with 2.69 Å RMSD with
respect  to  the  crystal.  Despite  the  new conformation  of  the  system,  K53 still  conserves  the
specific lysine-glutamine lock of kinases. 
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For the JAK-II system, in the growing of a phenyl onto the core of the crystal 3E62 (Figure
S2),  FragPELE  was  able  to  relocate  the  aspartic  acid  side-chain  to  accommodate  the  six-
membered ring of the fragment with a 1 Å RMSD. Lastly, for the BACE system, in 4DJW we
reproduced a crucial interaction between a structural water present in the crystal and the ligand
(Figure S3). This interaction locks the conformation of the ligand and enthalpically favors the
position of the explicit water.
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Figure 4.  Growing of the fragment (purple) onto the core (orange) to reproduce PDB 4CC6
(green). Yellow dashed lines are highlighting the interactions between the surrounding residues
of the receptor and the trifluoride of the fragment. 
Regarding  cryptic  sub-pockets,  we  used  the  epidermal  growth  factor  receptor  (EGFR),  a
tyrosine kinase frequently overexpressed in many types of cancers.49 Here, we focused on the
development of lapatinib,6 which was created by extending gefitinib5 seeking to target a novel
ligand-induced cavity next to the ATP binding site. FragPELE results are shown in Figure 6
where we observe how the ligand fragment pushes M766 away and concertedly moves F856
closer to the grown phenyl to produce a stabilizing pi-pi stack interaction. As it is seen in Figure
S4, all amino acids that were originally lining close to the fragment in lapatinib X-ray are also
present in the model. The pi-pi stack between F856 is not represented in the model because the
18
flip  of  180º  of  the  ring  (Figure  S5),  which  interposes  the  fluorine  atom;  however,  centroid
distances (5.7 Å) and angles (54º) are close to suitable conditions for this kind of interaction.
Figure 5. Growing of naphthyl (purple) and amino fragments from the core of 1W7H (orange) to
reproduce the crystal structure 1WBW (in green). The addition of the naphthyl fragment moves
K53 in order to allow the pi-cation, favoring the interaction between K53 and E71, which is
present in the crystal.  Subsequently,  the addition of the amino fragment is creating a second
interaction with H107. Thus, all native interactions present in 1WBW were recovered. 
In order to verify FragPELE does not generate false positives when growing a bulky R-group,
the binding mode of three p38 ATP-inhibitors with a common scaffold was predicted. Two of the
fragments confer higher potency (low nM) whereas the other one presents lower affinity (low
μM)  than  the  reference  compound  due  to  a  very  bulky  R-group (Table  S4).  Binding  pose
predictions  are  shown  in  Figure  7,  where  it  is  observed  that  the  addition  of  cyclohexane
promoted the displacement of the ligand outside the cavity (Figure 7, yellow model), losing the
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canonical hinge interaction with M109 (a backbone interaction). This contact, still present in the
other two ligands, is well known to account for a great part of the binding affinity, suggesting
that the cyclohexane ring is too big to fit into the ATP binding site, probably causing a decrease
of binding potency due to steric effects.
Figure 6.  Cross-growing of lapatinib from gefitinib.  Result (in blue) onto the initial  protein-
ligand complex (in gray). M766 moves aside allowing the fragment to grow and the F856 re-
orients towards the fragment aromatic group.
Backbone RMSD was also analyzed for the different  systems, please refer  to the “Protein
structure analysis” section  of the Supplementary  information.  We have obtained low RMSD
values for those systems with lower mobility (MUP-1, DNA ligase, BACE and lysozyme), and
higher ones in kinases (p38 and JAK-II), which have more flexibility (Table S10). However, all
protein RMSD were quite low (between 1.16 and 4.67Å) and we could consider that side chain
rearrangements were fundamental to reproduce crystal structures.
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Growing  and  scoring.  The  structural  validation  indicated  that  FragPELE  is  capable  of
correctly predicting the ligand-bound geometry within a binding site after R-group growth, even
in cases where significant MW gains are involved. As a final step,  we assessed whether the
interaction  energies  generated  for  the  grown  R-groups  could  be  used  to  rank  the  grown
molecules  in  a H2L stage.  PELE‘s  interaction  energy typically  discriminates  well  ligands of
similar size against the same target. Thus, we hypothesize that they may work when trying to
relatively score ligands with a common structural core; where we expect differences in entropic
terms to be small compared to the change in enthalpy. The chosen benchmark involves the FEP+
original study,37 which allowed us to compare our technique with state of the art techniques such
as Glide, MMGBSA, and FEP+. Hence, this benchmark only assessed the accuracy of FragPELE
at growing and scoring fragments but also if the software falls midway between the accurate but
expensive FEP and the cheap but sometimes inexact docking algorithms. 
Figure 7. Growing of several fragments to create three different inhibitors of p38 type II. 1A9U
(purple) and CHEMBL69929 (blue) correspond to binders with significantly higher affinity, and
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CHEMBL71403 (yellow) as the lowest affinity. In gray it is represented the position of the core
structure, derived from crystal 1A9U where we deleted the fluorine and methanesulfonyl groups.
Notice that the models of 1A9U and CHEMBL69929 keep the canonical interaction with M109,
contrary to CHEMBL71403.
A complete view of the results is shown in Table 2; individual correlation energy plots are
shown in Figures S6-S10. The correlations obtained with FragPELE are only slightly worse than
FEP+ for lysozyme, DNA ligase,  and JAK-II systems. We obtain similar results  as FEP+ in
MUP-I and, surprisingly, outperform FEP+ in the p38 results. Moreover, our results are clearly
better than  Glide SP scores for almost all systems as the latter does not account for side-chain
flexibility. However, for p38 and lysozyme, which have a low MW correlation,  Glide (SP and
Induced-Fit), and MMGBSA perform poorly, while FragPELE and FEP+ obtain good correlation
values. Finally, for JAK-II (0.32 MW correlation) all methods seem to struggle, with only FEP+
achieving an acceptable correlation (0.64).
Table 2. FragPELE results  overview and comparison to experimental  data between different




















Lysozyme 181L 0.64 0.79 0.32 0.28 0.40 0.3 0.32
DNA 
ligase
4CC5 0.88 0.98 0.36 0.75 0.01 0.36 0.92
MUP-I 1I06 0.96 0.94 0.92 0.84 0.86 0.75 0.93
JAK-II 3E62 0.48 0.64 0.50 0.19 0.50 0.21 0.32
p38 1W7H 0.87 0.69 0.09 0.50 0.01 0 0.63
* R² directly extracted from FEP+ benchmark.
Interestingly, FEP+ outperforms FragPELE in terms of accuracy when ranking systems where
the MW correlation is lower than 0.5. However, both of them perform similarly when the gain of
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further interactions (additional mass) between fragment and receptor accounts for the affinity
change. This seems to indicate that enthalpic contributions might be described accurately enough
with our simpler technique. We remind here that our score is simply the mean of the lowest 25%
force field interaction energies (see Methods section); a significance source of error might come
from the lack of explicit solvent and entropic effects (both accounted for in FEP techniques). 
Regarding computing time, FragPELE takes an average of one hour per fragment on 48 Intel
Xeon Platinum 8160 processor and can be run on any commodity CPU cluster. Therefore, its
computational cost falls midway between FEP and docking, but still accounting for the dynamics
of the ligand-protein system. 
CONCLUSIONS
In this  paper,  we performed the  first  benchmarks  of  FragPELE as  a  method for  dynamic
fragment growing, where we tested its potential for predicting protein-bound geometries and for
assessing the affinities of the grown ligands within congeneric series. Structural results show
good correlations between crystallographic data and predicted structures, even in cross-growing
tests  where  the  grown  derivatives  imply  significant  geometric  receptor  accommodation.
Predictions  for  some  cases  show  a  clear  improvement  when  explicit  water  molecules  are
incorporated.  For this reason, in prospective studies, the water position should be determined
through the previous knowledge of the system (using, for example, specific software such as
WaterMap).50 Other limitations of this first version include the requirement of growing from a
hydrogen atoms, cycle addition and core atoms transformations; we are working on solving all
these issues in the next version.  Regarding the size,  there is no limit  in the fragments being
added, large fragments, however, might result in strong steric clashes and introduce unrealistic
poses.  Importantly,  FragPELE seems promising at  locating which areas of a binding site are
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prone  to  opening  up  unexpected  sub-pockets  when  probed  with  specific  R-groups,  which
warrants further efforts to benchmark the technology. Interestingly,  while FragPELE was not
designed to provide  free binding energies, its score was compared to FEP+,  Glide SP, Glide
Induced-Fit, and MMGBSA, clearly outperforming the  three last  techniques  and providing a
close answer to the significantly more computationally intensive FEP+ method. 
In summary, the combination of our adaptive Monte Carlo sampling with a stepwise growing
algorithm  allows  the  ligand-receptor  complex  to  rapidly  adapt  while  exploring  the  most
significant areas of the potential energy surface. 
SUPPORTING INFORMATION
Tables  showing the  chemical  compounds  used  in  the  benchmark,  and extra  figures  of  the
models and diagrams to support the explanation of the results (PDF).
FragPELE code is available in GitHub: https://github.com/carlesperez94/frag_pele
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